Cargando…
Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
INTRODUCTION: Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35–60% of all HCV infections. There are limited data on resistance-associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353306/ https://www.ncbi.nlm.nih.gov/pubmed/37231989 http://dx.doi.org/10.1159/000528178 |
_version_ | 1785074687372427264 |
---|---|
author | Maunye, Tshegofatso K. Gededzha, Maemu P. Blackard, Jason T. Rakgole, Johnny N. Selabe, Selokela G. |
author_facet | Maunye, Tshegofatso K. Gededzha, Maemu P. Blackard, Jason T. Rakgole, Johnny N. Selabe, Selokela G. |
author_sort | Maunye, Tshegofatso K. |
collection | PubMed |
description | INTRODUCTION: Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35–60% of all HCV infections. There are limited data on resistance-associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes of treatment-naïve individuals with HCV genotype 5 infection at the Dr. George Mukhari Academic Hospital (DGMAH) in Pretoria, South Africa. METHODS: Nested PCR was performed to amplify the NS3/4A, NS5A, and NS5B genes. RAVs were evaluated using the Geno2pheno tool. RESULTS: In the NS3/4A gene, F56S and T122A were detected in one sample each. The D168E mutation was detected in 7 samples. Within the NS5A gene, the T62M mutation was detected in 2 individuals. In the NS5B gene, 8 of 12 individuals (67%) had the A421V mutation, while all 12 individuals (100%) had the S486A mutation. DISCUSSION: RAVs were detected frequently among treatment-naïve individuals with HCV genotype 5 infection in South Africa. Thus, resistance testing may be prudent when initiating treatment of patients with genotype 5 infection. Additional population-based studies are needed to understand the prevalence of these RAVs during HCV genotype 5 infection. |
format | Online Article Text |
id | pubmed-10353306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-103533062023-07-19 Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa Maunye, Tshegofatso K. Gededzha, Maemu P. Blackard, Jason T. Rakgole, Johnny N. Selabe, Selokela G. Intervirology Research Article INTRODUCTION: Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35–60% of all HCV infections. There are limited data on resistance-associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes of treatment-naïve individuals with HCV genotype 5 infection at the Dr. George Mukhari Academic Hospital (DGMAH) in Pretoria, South Africa. METHODS: Nested PCR was performed to amplify the NS3/4A, NS5A, and NS5B genes. RAVs were evaluated using the Geno2pheno tool. RESULTS: In the NS3/4A gene, F56S and T122A were detected in one sample each. The D168E mutation was detected in 7 samples. Within the NS5A gene, the T62M mutation was detected in 2 individuals. In the NS5B gene, 8 of 12 individuals (67%) had the A421V mutation, while all 12 individuals (100%) had the S486A mutation. DISCUSSION: RAVs were detected frequently among treatment-naïve individuals with HCV genotype 5 infection in South Africa. Thus, resistance testing may be prudent when initiating treatment of patients with genotype 5 infection. Additional population-based studies are needed to understand the prevalence of these RAVs during HCV genotype 5 infection. S. Karger AG 2023-05-09 /pmc/articles/PMC10353306/ /pubmed/37231989 http://dx.doi.org/10.1159/000528178 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Research Article Maunye, Tshegofatso K. Gededzha, Maemu P. Blackard, Jason T. Rakgole, Johnny N. Selabe, Selokela G. Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa |
title | Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa |
title_full | Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa |
title_fullStr | Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa |
title_full_unstemmed | Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa |
title_short | Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa |
title_sort | hepatitis c virus genotype 5 variability in treatment-naïve patients in south africa |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353306/ https://www.ncbi.nlm.nih.gov/pubmed/37231989 http://dx.doi.org/10.1159/000528178 |
work_keys_str_mv | AT maunyetshegofatsok hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica AT gededzhamaemup hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica AT blackardjasont hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica AT rakgolejohnnyn hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica AT selabeselokelag hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica |